UHC Medicare Advantage: October 2026 Testing Policy Revisions

Lyme Disease, Testosterone, Vitamin B12 and Chronic Heart Failure Testing Criteria Updated

Rcmaxis Billing & Policy Update  ·  Posted October 20, 2026  ·  Effective: October 2026 billing cycle

Summary of the Rule or Edit Change

UHC's Medicare Advantage Reimbursement Policy (MEDADV RPUB) update for October 2026 revises four separate lab and diagnostic testing policies: Lyme disease testing, testosterone testing, vitamin B12 testing, and testing related to chronic heart failure management. Unlike a benefit-level change, these are code-level revisions, meaning UHC adjusted which specific diagnosis codes, frequency limits, or testing combinations pass its medical-necessity edits for Medicare Advantage claims.

Each of the four areas has its own clinical logic. Lyme disease and vitamin B12 testing policies typically govern which ICD-10 codes justify ordering the test and how often it can be repeated in a benefit period. Testosterone testing policies usually tie coverage to documented signs or symptoms of hypogonadism rather than screening alone. Chronic heart failure testing (BNP/NT-proBNP and related labs) policies often set frequency limits tied to disease staging or a recent exacerbation.

Because this bulletin updates four policies at once, the practical risk for labs, primary care practices and cardiology groups billing UHC Medicare Advantage is the same across all four: a claim built against last month's diagnosis-code or frequency logic can now fail an edit it used to pass, or in some cases newly pass an edit it used to fail. Either direction matters for revenue; you want to catch a now-failing edit before a batch of claims denies, and you want to catch a now-passing edit so you're not writing off tests that are newly covered.

Action Required for Billing Teams

Pull the full October 2026 MEDADV RPUB bulletin and read all four affected sections individually rather than relying on a summary, since each test category has its own diagnosis-code list and frequency rule, and the direction of the change (tightened versus loosened) isn't the same across all four.

Weigh this by volume. A primary care or cardiology group ordering vitamin B12 and chronic heart failure labs regularly on a Medicare Advantage panel of a few hundred patients can see a meaningful swing in clean-claim rate from a single quarter's policy revision if nobody updates the local edit rules; even a handful of newly-failing claims a week adds up over a quarter, and newly-passing claims that get written off out of habit are revenue left on the table.

Our laboratory billing guide and Medicare Advantage billing guide cover how MA plan-specific reimbursement policies differ from standard Medicare coverage rules.